CLAYRIG + cyclophosphamide + methylprednisolone

This drug entry refers to a specific combination immunotherapy regimen evaluated by Assistance Publique - Hôpitaux de Paris (AP-HP) for the treatment of anti-Hu-associated paraneoplastic sensory neuronopathy. The regimen consists of **CLAYRIG**, a 10% (100 mg/mL) intravenous immunoglobulin (IVIG) solution, combined with the immunosuppressant **cyclophosphamide** and the corticosteroid **methylprednisolone**. The protocol is designed for early administration to mitigate autoimmune-mediated neuronal damage before it becomes irreversible. CLAYRIG, manufactured by LFB, provides passive immunity and modulates the immune system by neutralizing autoantibodies and interacting with Fc receptors. Cyclophosphamide acts as a DNA alkylating agent to suppress the underlying autoimmune response, while methylprednisolone provides potent anti-inflammatory effects through glucocorticoid receptor agonism.

Brand names

CLAYRIG

Other names

Early combination immunotherapy (IVIG, cyclophosphamide, methylprednisolone)Immunoglobulins IV (CLAYRIG) + Cyclophosphamide IV + Methylprednisolone IV